1. Introduction
===============

Coronary heart disease (CHD) and its subsequent complications remain the leading cause of morbidity and mortality worldwide. Yet its etiology, which is multifactorial with environmental and genetic factors influences, remains elusive.^\[[@R1]\]^ A common cause of CHD is the occurrence of atherosclerotic processes in various areas of the circulatory system. Factors affecting the development of coronary atherosclerosis include age, smoking, obesity, hypertension, and diabetes. The role of oxidative stress in CHD progression has been increasingly recognized in the past few decades.^\[[@R2]\]^

Paraoxonase 1 (PON1) is located on high-density lipoprotein cholesterol (HDL-C) and has been shown to have antioxidant potential, mainly by protecting low-density lipoprotein cholesterol (LDL-C) and HDL-C against oxidative processes.^\[[@R3]\]^ PON1 is synthesized mainly in the liver, but some is secreted into the bloodstream, where it associates with HDL-C. The human PON1 gene is located on the long arm of chromosome 7 at q21.3, which includes 8 introns and 9 exons.^\[[@R4]\]^ Several polymorphisms in the exons and promoter region of the PON1 gene have been investigated in numerous studies for their association with CHD. PON1 Q192R (rs662 A\>G) polymorphism, which is an amino acid substitution at codon 192 glutamine (Q) to arginine (R) substitution, has been suggested to be associated with the susceptibility of CHD. PON1 Q192R polymorphism gives rise to 2 alloenzymes. It has been shown that the R alloenzyme is less effective in inhibiting the oxidation of LDL-C, for it hydrolyzes lipid peroxides to a lesser degree.^\[[@R5]\]^ A meta-analysis showed that the Q192R polymorphism has a significant risk (7% per R allele) for CHD.^\[[@R6]\]^ Another independent meta-analysis estimated a 10% risk excess per R allele for CHD.^\[[@R7]\]^ However, in a recent published meta-analysis study, significant association was found between the PON1 gene Q192R polymorphism and heart diseases risk only in Asian and African populations.^\[[@R8]\]^

Up to now, several studies investigated the role of the PON1 Q192R polymorphism on the risk of CHD in Chinese population. Liu et al^\[[@R9]\]^ showed that PON1 Q192R polymorphism is significantly associated with susceptibility of coronary artery disease (CAD) in the Chinese Han population, and the 192R allele might be an independent predictor for CAD. However, the results were inconclusive. In another study, there was no significant association between the PON1 gene Q192R polymorphism and CHD risk.^\[[@R10]\]^ Therefore, we performed the present meta-analysis to evaluate the association between the PON1 gene Q192R polymorphism and CHD risk. To our knowledge, this is the first comprehensive meta-analysis concerning the association between the PON1 gene Q192R polymorphism and CHD risk in Chinese.

2. Materials and methods
========================

2.1. Study selection
--------------------

To identify all the articles that examined the association of the PON1 Q192R polymorphism with CHD, we conducted a comprehensive search of the PubMed, EMBASE, and China National Knowledge Infrastructure databases (the last searching update was December 22, 2017). Search terms included paraoxonase or PON or PON1 or Q192R; gene, polymorphism, genotype, or genetic variant; and myocardial infarction, myocardial ischemia, ischemic heart disease, CHD, CAD, cardiovascular disease, angina, acute coronary syndrome, acute coronary syndromes, coronary calcification, ischemic heart failure, heart failure, or ischemic cardiomyopathy.

Eligible studies were included that fulfilled the following criteria: association studies were unrelated case--control design; evaluation of PON1 Q192R polymorphism with the risk of CHD in Chinese population; complete data with genotype frequencies; and subject investigated: CHD patients and normal controls. Data from a study presented only in the form of an abstract were not included. Duplication studies were not included. Studies without genotype frequency were excluded if the relevant information could not be obtained from the authors. Hardy--Weinberg equilibrium (HWE) was also checked for each eligible study and the studies whose control groups failed HWE were not included. We also screened references of original studies and review articles by a hand search. Ethical committee approval was not necessary for the present meta-analysis. Because all the data in this meta-analysis was extracted from existing literature, and this meta-analysis was not involving handling of individual patient data.

2.2. Quality assessment
-----------------------

This meta-analysis was conducted according to the PRISMA guidelines.^\[[@R11]\]^ Two reviewers (ZZ and JO) independently assessed the quality of all included studies using according to the Newcastle--Ottawa Scale (NOS) (available at <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). This scale uses a domain-based system to assess the quality of a study involving patient selection, comparability, and assessment of outcome, with scores ranging from 0 (worst) to 9 (best). Studies were considered to be of poor quality (scores of \<4), medium quality (scores of 4--6), and high quality (scores of 7--9).

2.3. Data extraction
--------------------

For each study, that met our criteria, the following parameters were collected: first author\'s last name, year of publication, criteria of diagnosis, number of cases and controls, genotype distribution, genotyping methods, allele frequency, and the *P* value for HWE in control participants. All the searching work and data extraction work were conducted by 2 authors (ZZ and JO) independently and they reached a consensus on all items.

2.4. Statistical analysis
-------------------------

The strength of the association between the PON1 Q192R polymorphism and CHD was measured by odds ratio (OR) corresponding to 95% confidence interval (CI) according to the method of Woolf.^\[[@R12]\]^ Heterogeneity of between studies was assessed by Cochran chi-squared-based Q statistic test.^\[[@R13]\]^ Substantial heterogeneity was considered when the *P* value for heterogeneity was \<.05 and a random-effects model using the DerSimonian and Laird method^\[[@R14]\]^ was adopted to pool the results; otherwise, a fixed-effects model using the Mantel--Haenszel method was used.^\[[@R15]\]^ In order to better evaluate the extent of heterogeneity between studies, the *I*^2^ test was also used. This statistic yields result ranging from 0% to 100% (*I*^2^ = 0--25%, no heterogeneity; *I*^2^ = 25--50%, moderate heterogeneity; *I*^2^ = 50--75%, large heterogeneity; *I*^2^ = 75--100%, extreme heterogeneity).^\[[@R16]\]^ For the PON1 Q192R polymorphism, we investigated the associations between the genetic variant and CHD risk in homozygous model (R/R vs Q/Q), recessive genetic model (R/R vs Q/R + Q/Q), dominant genetic model (R/R + Q/R vs Q/Q), and allele model (R vs Q).^\[[@R17]\]^ The significance of the pooled OR was determined by the Z-test (*P* \< .05 suggests a significant association).

To examine specific subsets in these studies, separate analyses were used. Sensitivity analysis was performed to assess the influence of each study in which 1 single study was removed each time. Publication bias was investigated by Begg funnel plots^\[[@R18]\]^ and Egger linear regression test.^\[[@R19]\]^ The Duval and Tweedie nonparametric "trim and fill" procedure was adopted to further assess the possible effect of publication bias in our meta-analysis.^\[[@R20]\]^ Statistical analyses were all carried out using the STATA software package v 12.0 (Stata Corporation, College Station, TX). All the *P* values were 2 sided.

3. Results
==========

3.1. Literature search and study characteristics
------------------------------------------------

The PRISMA flow diagram of study exclusion and inclusion with specific reasons is shown in Fig. [1](#F1){ref-type="fig"}. Four hundred eighty-nine eligible studies were identified by our search strategy. Four hundred fifty studies were excluded after title and abstract screening using the predefined inclusion and exclusion criteria. Then full-text articles were retrieved for assessment in detail. In the end, 13 studies investigated the association between the PON1 Q192R polymorphism and risk of CHD was selected in this meta-analysis with 4353 cases and 4882 controls.^\[[@R9]--[@R10],[@R21]--[@R31]\]^ Characteristics of included studies are summarized in Table [1](#T1){ref-type="table"}. The most commonly used genotyping method in these studies was polymerase chain reaction--restriction fragment length polymorphism. Quality assessments by the NOS scores of the eligible studies are listed in Table [1](#T1){ref-type="table"}. All 13 included studies in the meta-analysis yielded scores ≥6, indicating the methodological quality was relatively good.

![PRISMA flow diagram of the study selection process.](medi-97-e11151-g001){#F1}
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Characteristics and quality control of included studies of PON1 Q192R polymorphism.
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3.2. Meta-analysis of the PON1 Q192R polymorphism
-------------------------------------------------

For the PON1 Q192R polymorphism and its relationship to CHD, large heterogeneity was found under allele model (*I*^2^ = 60.5%, *P* = .002), homozygous model (*I*^2^ = 60.7%, *P* = .002), and dominant model (*I*^2^ = 54.0%, *P* = .011). Therefore, a random-effects model was adopted to pool the results. Moderate heterogeneity was found under the recessive model (*I*^2^ = 49.4%, *P* = .022), so the Mantel--Haenszel fixed-effects model was applied.

Forest plots of overall analyses with different models on the association between the PON1 Q192R polymorphism and risk of CHD are shown in Figs. [2](#F2){ref-type="fig"} to [5](#F5){ref-type="fig"}. Significant statistical association was observed between the PON1 Q192R polymorphism and CHD under the recessive genetic model (R/R vs Q/R + Q/Q, OR = 1.111, 95% CI = 1.017--1.214) (Fig. [2](#F2){ref-type="fig"}). We observed no statistical association between PON1 Q192R polymorphism and risk of CHD under the allele model (R vs Q, OR = 1.087, 95% CI = 0.976--1.209) (Fig. [3](#F3){ref-type="fig"}), homozygous model (RR vs QQ, OR = 1.192, 95% CI = 0.949--1.496) (Fig. [4](#F4){ref-type="fig"}), and dominant genetic model (Q/R + R/R vs Q/Q, OR = 1.127, 95% CI = 0.938--1.354) (Fig. [5](#F5){ref-type="fig"}).

![Forest plot of the association between the PON1 Q192R polymorphism and the risk of coronary heart disease under recessive model. CI = confidence interval, OR = odds ratio.](medi-97-e11151-g003){#F2}

![Forest plot of the association between the PON1 Q192R polymorphism and the risk of coronary heart disease under allele model. CI = confidence interval, OR = odds ratio.](medi-97-e11151-g004){#F3}

![Forest plot of the association between the PON1 Q192R polymorphism and the risk of coronary heart disease under homozygote model. CI = confidence interval, OR = odds ratio.](medi-97-e11151-g005){#F4}

![Forest plot of the association between the PON1 Q192R polymorphism and the risk of coronary heart disease under dominant model. CI = confidence interval, OR = odds ratio.](medi-97-e11151-g006){#F5}

3.3. Sensitivity analysis and publication bias
----------------------------------------------

To investigate the influence of individual study of the PON1 Q192R polymorphism sets on the pooled ORs, we deleted a single study involved in the meta-analysis each time. The pooled ORs were not influenced significantly by removal of each individual study under the 4 genetic models (Fig. [6](#F6){ref-type="fig"}A--D), which suggest the results of this meta-analysis were stable.

![The sensitivity analysis of coronary heart disease risk associated with PON1 Q192R polymorphism. (A) Recessive model. (B) Allele model. (C) Homozygote model. (D) Dominant model.](medi-97-e11151-g007){#F6}

For the PON1 Q192R polymorphism, the shape of Begg funnel plots showed no obvious asymmetry (Fig. [7](#F7){ref-type="fig"}A--D). As weighed by the Egger test, there was a low probability of publication bias, except under the homozygote model (Egger test: *P* = .040) (Table [2](#T2){ref-type="table"}). We then undertook a sensitivity analysis using the trim and fill method. As estimated by the trim-and-fill method, no missing studies were required to make the filled funnel plots symmetrical under the homozygote model (data not shown). The results of Egger test showed no obvious publication bias in overall models (Table [2](#T2){ref-type="table"}).

![Begg funnel plot for publication bias test of the PON1 Q192R polymorphism with pseudo 95% confidence limits. (A) Recessive model. (B) Allele model. (C) Homozygote model. (D) Dominant model. Each point represents a separate study for the indicated association. Horizontal line represents the mean effects size.](medi-97-e11151-g008){#F7}
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The result of Begg and Egger tests.
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4. Discussion
=============

The present meta-analysis, including 4353 case-patients and 4882 controls from 13 case--control studies, evaluated the association between the PON1 Q192R polymorphism and CHD in Chinese. Significant statistical association was observed between the PON1 Q192R polymorphism and CHD under recessive genetic model, as well as no association under allele model, homozygote model, and dominant model. Overall, the PON1 Q192R polymorphism has a weak association with CHD risk, the 192R allele may be a risk factor to develop CHD in Chinese. Compared with the previous meta-analysis, Hernández-Díaz et al^\[[@R8]\]^ evaluated 64 studies and concluded that no association was observed between the CHD risk and the PON1 Q192R polymorphism. However, in the stratified analysis by specific ethnicity, they found that the Q192R polymorphism had a protective association with heart diseases in Asian people but not in European or American populations. Another meta-analysis reported that there is no robust evidence that the PON1 Q192R polymorphism is associated with CHD risk in Caucasian women or men.^\[[@R7]\]^ In a recent meta-analysis, Wang et al^\[[@R32]\]^ evaluated 76 studies and showed an overall weak association between the R192 polymorphism and CHD risk. However, when studies were stratified for ethnicity, no significant association was found for East Asian in all genetic models. This inconsistency between the prior and present results may have at least 2 possible explanations. First, the genetic effect of the PON1 Q192R polymorphism might be race-specific. They did not take into account the genetic differences between ethnicities, and their results may not suitable for the Chinese. Second, epidemiological factors, such as age, gender, and life style, might explain the discrepancy across different ethnical populations.

Significant statistical association was observed between the PON1 Q192R polymorphism and CHD under the recessive genetic model. We observed no statistical association between PON1 Q192R polymorphism and risk of CHD under the allele model, homozygous model, and dominant genetic model. PON1 is an HDL associated enzyme and has been shown to have antioxidant and anti-inflammatory potential.^\[[@R3]\]^ The polymorphism Q192R might modulate enzymatic activity. Liu et al^\[[@R9]\]^ observed that individuals who carried the RR or QR genotype had lower plasma PON1 activity toward phenylacetate (AREase) activity than QQ homozygotes in Chinese. Therefore, RR genotypes might have reduced the capacity of HDL to prevent the oxidation of LDL, thus leading to a high risk of CHD.

The pooled ORs were not influenced significantly by removal of each individual study under the 4 genetic models, which suggest the results of this meta-analysis were stable. Furthermore, the Egger test and the filled funnel plots indicated no obvious evidence of publication bias in this meta-analysis, suggesting that the results were relatively stable. In the meta-analysis significant heterogeneity was found under allele model, homozygous model, and dominant model. In this study, publication year, genotyping method, and sample size could account for heterogeneity. Therefore, we conducted sensitivity analysis and found that the overall pooled ORs were not influenced significantly by removal of each individual study under the 4 genetic models, which suggest the results of this meta-analysis were stable. Moreover, other strength of our study is the quality of included studies which was evaluated by the NOS scores.

Limitations of this meta-analysis must be considered. First, the number of qualified studies was relatively small. Second, all enrolled studies were case--control design. Third, because of the limited data, we could not analyze the environmental modification factors such as smoking, alcohol intake, physical activities, and diets in current meta-analysis. Fourth, only the articles published in English or in Chinese were selected, potentially causing a language bias.

In conclusion, this meta-analysis provided evidence that the PON1 Q192R polymorphism has a weak overall association with CHD risk in Chinese. Considering the limitations mentioned above, large sample size and well-designed epidemiologic studies are needed to provide sufficient power to estimate the association between the PON1 Q192R polymorphism and CHD in Chinese.
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